BTC iShares MSCI EAFE Growth ETFMost RecentCompany & Industry OverviewsDoubtful about Roche’s Bladder Cancer Treatment? Look at StudiesRoche (RHHBY) noted that Tecentriq was granted Breakthrough therapy designation for use in the treatment of NSCLC.
Company & Industry OverviewsDoubtful about Roche’s Bladder Cancer Treatment? Look at StudiesRoche (RHHBY) noted that Tecentriq was granted Breakthrough therapy designation for use in the treatment of NSCLC.
